2023-08-03 06:31:33 ET
- Regeneron Pharmaceuticals press release ( NASDAQ: REGN ): Q2 Non-GAAP EPS of $10.24 beats by $0.34 .
- Revenue of $3.16B (+10.5% Y/Y) beats by $140M .
- "Regeneron delivered strong financial results in the second quarter of 2023 through increasingly diversified revenue streams, and we remain well-positioned for long-term growth," said Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron. "In the past months, we have continued to advance our pipeline, in particular aflibercept 8 mg which we are progressing towards a potential FDA decision in the third quarter and for which we shared unprecedented two-year results in the pivotal PHOTON trial demonstrating durable vision gains at extended dosing intervals in patients with diabetic macular edema."
For further details see:
Regeneron Pharmaceuticals Non-GAAP EPS of $10.24 beats by $0.34, revenue of $3.16B beats by $140M